David Tierney

Recruited as CEO for a new ophthalmic company spun out of Harvard/Mass Eye & Ear. Aramis is developing a novel cytokine antagonist - A197 for the treatment of Dry Eye Disease (DED) and other ocular surface conditions. Successfully completed a $10.5M series A financing in October 2021. IND for A197 submitted in November and phase II DED study initiated in January 2022.

Recruited by Board of Directors to develop a commercial strategy for PB2001, a novel combination product for the treatment of Parkinson’s Disease. PB2001 successfully completed Phase III studies.

Hired by the Board of Directors to lead the company and oversee the development of BPX 01 for Acne and BPX 04 for Rosacea. Merged with Timber Pharmaceuticals in May 2020.

Recruited by Investors to oversee the development of DEXYCU, a novel intracameral injection for the treatment of post cataract surgery inflammation. DEXYCU was approved by FDA in February 2018 and subsequently Icon was acquired by EyePoint Pharmaceuticals (NASDAQ:EYPT). Drug approval: DEXYCU – Post Cataract Surgery Inflammation – February 2018

Co-founded Oceana Therapeutics, serving as President and COO. Oceana acquired the worldwide rights to DEFLUX®, a medical device to treat pediatric Vesical Urinary Reflux, and SOLESTA® an investigational device to treat fecal incontinence from Q-Med AB Sweden. The transaction was financed by Kelso, a NYC private equity firm and Frazier Healthcare Partners. With the acquisition of DEFLUX, Oceana launched a sales force in the United States and Europe and a worldwide distribution network in an additional 20 countries. SOLESTA was approved by FDA in May 2011 and was launched with an expanded sales force calling on colorectal surgeons in September 2011. Oceana was acquired by Salix Pharmaceuticals (NASDAQ:SLXP) in December 2011 for $300 million.

Recruited to transform HydroMed Sciences (later renamed Valera Pharmaceuticals), a research subsidiary of GP Strategies GPX (NYSE), into a fully integrated specialty pharmaceutical company. Valera emerged as a urology/endocrinology focused company raising over $65 million in funding, including $35 million raised in a successful 2006 IPO. The company built a management team of pharmaceutical professionals, established a product development pipeline, and commercialized Valera’s proprietary Hydron implant technology, with the October 2004 FDA approval of VANTAS, a 12-month implant for the palliative treatment of advanced prostate cancer. Additionally, oversaw the establishment of Valera’s own manufacturing facilities in Cranbury NJ and a sales force launching VANTAS within weeks of approval. In 2006, Valera acquired an additional urology product VALSTAR, a treatment for bladder cancer. In 2007, SUPPRELIN LA a 12-month implant product for the treatment of Central Precocious Puberty was approved by FDA. Valera was acquired in April 2007 by Endo Health Solutions, Inc (NYSE: ENDP). Drug approval: VANTAS – Palliative Treatment of Prostate Cancer – October 2004 Drug approval: SUPPRELIN LA – Hormonal suppression in Central Precocious Puberty – May 2007